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Cardiovascular Death in Uremia—More Complex
Than We Thought
Eberhard Ritz
A brief overview is provided of the history of cardiovascular complications in renal disease and the underlying
pathomechanisms involved in the acceleration of atherogenesis in the earliest stages of renal malfunction.
Coronary artery disease versus cardiomyopathy as the cause of cardiac death in renal patients is discussed.
Interventions to attenuate the progression of chronic kidney disease, such as blood pressure lowering, treatment
with statins and beta-blockers, and blockade of the renin-angiotensin system, are also covered. [Hong Kong J
Nephrol 2008;10(1):7–13]
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HISTORY OF CARDIOVASCULAR COMPLICATIONS
IN RENAL DISEASE
When maintenance hemodialysis became available,
it was—somewhat naively—widely thought that
washing out uremic toxins would prolong the life
expectancy of uremic patients to the level found in
the general population. A report from Seattle where
maintenance hemodialysis had started came as a rude
surprise when it indicated that almost 50% of the
patients initially on maintenance hemodialysis had
died within slightly more than 10 years time, mostly
from cardiac causes. The authors postulated that
atherosclerosis is accelerated in patients on prolonged
hemodialysis [1]. The high cardiovascular mortality
of patients on dialysis has been widely confirmed and
found to be higher than in the background population
by a factor between 5 and 500 depending on age [2].
Nevertheless, it had remained controversial for a long
time whether excess cardiovascular mortality was
actually due to specific acceleration of atherogenesis,
because an alternative possibility had not convincingly
been excluded, i.e. that the high cardiac death rate
resulted from the high prevalence of classical
cardiovascular risk factors.
Meanwhile, it has been firmly established that
cardiovascular risk starts very early in chronic kidney
disease (CKD). Unexpectedly, it was found that even
in advanced CKD, the risk to go on renal replacement
therapy is substantially lower than the risk to die, mostly
from cardiovascular causes [3] (Table 1).
The recognition that even minor renal dysfunction
predicts elevated mortality goes back to the
Hypertension Detection and Follow-up Program
(HDFP), which documented a significant increase in
10-year mortality even for patients with serum
creatinine concentrations between < 1.2 mg/dL and 2
mg/dL [4]. A more recent study from Belgium
calculated estimated glomerular filtration rate (eGFR)
in apparently healthy individuals and noted that the risk
of death was increased even within the bracket of eGFR
values 89.4–104.3 mL/min/1.73 m2 [5] (Table 2).
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The risk conferred by impaired renal function is
particularly high in patients suffering from coronary
events or cardiac malfunction. In patients with
creatinine clearance > 75 mL/min undergoing
myocardial infarction, inhospital mortality was 2% [6].
In contrast, in patients with creatinine clearance 50–75
mL/min, it was increased by a factor of 3 (6%
mortality), and in end-stage renal disease by a factor of
15 (30% mortality). Similarly, the post-discharge death
rate was strikingly increased in CKD. It has recently
been noted that GFR alone is not the only determinant.
At any given level of GFR, the cardiac risk is increased
if the patient has proteinuria [7], and this is true even
for microalbuminuria [8].
UNDERLYING PATHOMECHANISMS
Recent experimental work [9,10] shows that in a genetic
model of accelerated atherogenesis, the apo E –/– mouse,
the rate of growth of aortic plaques is accelerated after
subtotal nephrectomy, but amazingly this is found even
after uninephrectomy. The study of Bursztyn et al [11]
documented in hypertensive patients that the coronary
calcium score increased more rapidly over a 3-year
observation period if eGFR was < 60 mL/min.
These observations raise the question about the
underlying pathomechanisms involved in such
acceleration of atherogenesis in the earliest stages of
renal malfunction.
Presumably, the most important factor is endothelial
dysfunction which is demonstrable even in early stages
of CKD. In the MMKD study, we noted in patients
with primary kidney disease that even when the
measured GFR was normal, the concentration of
ADMA (asymmetric dimethyl-L-arginine) was
increased [12]. This is presumably explained by the fact
that despite progressive loss of nephrons, whole kidney
GFR is initially kept normal by compensatory single
nephron hyperfiltration. The metabolically relevant
number of tubular epithelial cells is already diminished,
however. With respect to ADMA, this is important
because  b reakdown o f  ADMA v ia  DDAH
(dimethylarginine dimethylamino hydrolase) takes
place in tubular epithelial cells. Some further
abnormalities at this stage of CKD with normal whole
kidney GFR include: abnormal Apo lipoproteins [13,
14] and increased sympathetic activity [15]. In addition,
in patients with IgA-glomerulonephritis who were
normotensive according to the WHO criteria and had
normal GFR, we found already increased blood
pressure, particularly at night t ime. Further
abnormalities relevant to atherogenesis are found in
CKD and include: a proinflammatory state, indicated
by elevated high sensitivity C-reactive protein,
fibrinogen, interleukin-6 and intercellular adhesion
molecule; as well as a prothrombotic state, indicated
by increased D-dimers [16].
The ultimate culprit appears to be the endothelial
cell. An endothelial cell abnormality is suggested by
the observation of Landray et al [17]: in patients with
primary kidney disease, increasing quintiles of cystatin
C (a marker of GFR) are associated with progressively
elevated concentrations of von Willebrand factor. Von
Willebrand factor is an index of endothelial cell
dysfunction.
Table 1. At all stages of chronic kidney disease (CKD), death is a more common outcome than end-stage renal disease*
GFR (mL/min/1.73 m2) RRT (%) Death (%)
CKD stage
II 60–89 1.1 19.5
III 30–59 1.3 24.3
IV 15–29 19.9 45.7
*1996–2001: in 27,998 patients with GFR < 90 mL/min/1.73 m2. GFR = glomerular filtration rate; RRT = renal replacement therapy.
[From Reference 3.]
Table 2. In healthy individuals, the risk of cardiovascular death starts to rise at a GFR of 90 mL/min*
Quartiles eGFR (mL/min/1.73 m2) Mortality (standardized rate/1,000 person years) aHR (95% CI)
1 < 75.6 2.57 2.21 (1.13–4.32)
2 75.6–89.4 2.61 2.48 (1.26–4.87)
3 89.4–104.3 1.9 1.84 (0.90–3.71)
4 > 104.3 0.99 1
*In 8,913 randomly selected apparently healthy individuals over 10-year follow-up, modified MDRD, S-creatinine corrected (isotope
dilution mass spectrometry standard). eGFR = estimated glomerular filtration rate; aHR = adjusted hazard ratio; CI = confidence interval.
[From Reference 5.]
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Based on our partially unpublished experimental
studies [9], we propose the hypothesis summarized in
Table 3: minor derangements of renal function cause
dysfunction of endothelial cells with increased oxidative
stress as the presumed common denominator.
Apart from injury by a primary kidney disease,
another aspect deserves mention. Both experimental
studies [18] and human observations [8,19] document
that impaired intrauterine development is associated
with a diminished number of nephrons, thus introducing
a higher risk of microalbuminuria [19] and diminished
GFR [8]. This may be a complementary explanation
for the link between faulty prenatal programming and
increased risk in adult life with higher cardiovascular
as well as renal risk and event rates (Figure).
Diminished nephron number [20] in and by itself is
presumably not sufficient to lead to progressive renal
dysfunction, but may explain why individuals born with
low birth weight have higher albumin-creatinine ratios
at young adult age [21] and presumably experience
more rapid loss of renal function when in adult life and
additional renal insult occurs, e.g. diabetes, IgA
glomerulonephritis etc.
C O R O N A R Y  A R T E R Y  D I S E A S E  V E R S U S
CARDIOMYOPATHY
In the past, it was thought that the great majority of
renal patients die from coronary heart disease. Recent
studies, for instance the German 4-D study [22], found
that adjudicated coronary heart disease accounted for
only 9% of deaths whilst other cardiac causes accounted
for 35% (i.e. sudden death for 26%, heart failure for
6%, other cardiac causes for 3%). This finding prompted
us to argue that, apart from coronary disease,
cardiomyopathy is a major cause of cardiac death in
rena l  pa t i en t s .  Po ten t i a l  exp lana t ions  fo r
cardiomyopathy (Table 4) include inappropriate cardiac
hypertrophy (both of the left and right ventricle which
excludes hemodynamic causes as a simple explanation),
interstitial fibrosis and microvessel disease with wall
thickening of postcoronary arteries and microvessel
disease (capillary deficit and arteriolar thickening).
These alterations contribute to systolic dysfunction,
diastolic dysfunction and electrical instability in
patients with renal disease. Such cardiomyopathy starts
early on in the course of CKD. In unpublished studies,
Table 3. Endothelial cell dysfunction in chronic kidney disease
Minor derangements of renal function (microalbuminuria, loss of glomerular filtration)
● Dysfunction of endothelial cells
● Sensitizing vasculature to further injurious effects of
– hypertension
– dyslipidemia
– hyperglycemia
– ...
presumed common denominator: oxidative stress
Figure. Prenatal programming as one explanation for the link between the cardiovascular (CV) continuum and the renal continuum.
MI = myocardial infarction; GFR = glomerular filtration rate; ESRD = end-stage renal disease.
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we found that expansion of the cardiac interstitium,
reduction of the capillary density in the myocardium
and thickening of intramyocardial arteries occurred
even after uninephrectomy. The important role of
reactive oxygen species is suggested by the observation
that such abnormalities were completely prevented by
the administration of tempol, a superoxide-dismutase
agonist, which prevents formation of reactive oxygen
species.
INTERVENTIONS
The observation of excess cardiovascular mortality in
the early stages of CKD [3] is of course bad news, but
the good news is that all interventions that are necessary
to attenuate progression of CKD are also beneficial for
the heart (“what is good for the kidney is also good for
the heart”):
• lowering of blood pressure;
• blocking the renin-angiotensin-aldosterone
system;
• lowering lipids;
• cessation of smoking;
• fighting the metabolic syndrome and others.
This has led to recent discussions on whether kidney
disease should be considered as a coronary heart
equivalent, similar to diabetes mellitus for which
guidelines recommend interventions as if the patient
had survived myocardial infarction [23]. Timely
intervention in the early stages of CKD is also important
for another reason: in a somewhat underpowered study,
it was shown that in advanced CKD (stage IV or V),
multiple risk factor intervention as compared to
conventional care, i.e. intensified treatment, conferred
no longer significant benefit with respect to
cardiovascular events, carotid intima thickness and
brachial artery reactivity as an index of endothelial
function [24].
Unfortunately, only limited controlled prospective
evidence is available for the selection of treatments in
patients with advanced CKD. The importance of this
concern is illustrated by the observation that although
some parameters such as homocysteine [25] had been
highly predictive of cardiovascular events, yet their
(partial) correction failed to yield a significant benefit
as illustrated by the failure to lower homocysteine by
administering folate [26].
There have been a number of recent reports,
indicating that in observational studies, patients treated
with active vitamin D had lower all cause and
cardiovascular mortality [27]. This fascinating
observation must, however, again be confirmed by
prospective interventional data. Admittedly, however,
the fact that active vitamin D suppresses renin
expression in the juxtaglomerular apparatus [28]
provide a very strong rat ionale as do other
observations.
Interventions of (more or less) proven benefit
include lowering of blood pressure, lipid lowering, beta-
blocker treatment and blockade of the renin-angiotensin
system.
Blood pressure lowering
With respect to the optimal blood pressure on dialysis,
there has been considerable controversy. On the one
hand, the center in Tassin [29], using long slow dialyses,
noted that the 15-year survival was better by 24% in
patients whose mean arterial pressure was < 99 mmHg
(Table 5). Observational studies in patients on relatively
short-term dialysis showed: no relation of blood
pressure to survival (as did the German 4-D Study [22]);
a relation to low, and much less to high, predialysis
blood pressure [30,31]; a relation only to high pulse
pressure [32] as an index of aortic stiffening.
Table 4. Vascular disease versus cardiomyopathy in chronic kidney disease
Vascular disease Cardiomyopathy
Atherosclerosis (plaques) Inappropriate (LV+RV) hypertrophy
Arteriosclerosis (arterial stiffening) Interstitial fibrosis
MVD*
Systolic dysfunction, diastolic dysfunction, electrical instability
*Wall thickening of postcoronary arteries and capillary deficit. LV = left ventricular; RV = right ventricular; MVD = microvessel disease.
Table 5. Better survival of hemodialysis patients with low normal
as compared to upper normal blood pressure values: Tassin dialysis
center—patient survival as a function of mean arterial pressure
(MAP)
MAP (mmHg)
Patients surviving (%)
5 yr 10 yr 15 yr 20 yr
< 99 93 85 67 53
* 99 81 65 43 –
[From Reference 29.]
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The explanation for the contraintuitive survival
benefit of high and mortality excess at low blood
pressures in some studies is the presence of reverse
causality, i.e. the association between risk factors and
outcome is confounded by preexisting comorbidities.
In other words, if patients are no longer able to generate
a sufficiently high blood pressure because of cardiac
disease, they die—not (at least not exclusively) because
blood pressure is low, but because of concomitant heart
malfunction that no longer allows them to generate a
normal or high blood pressure.
In our view, low blood pressure in patients relatively
recently accepted for maintenance hemodialysis is a
predictor of early mortality, while low blood pressure
in patients on long-term hemodialysis with more
optimized dialysis schedules (particularly long slow
dialysis) is a predictor of better survival. It follows that
the issue of whether or not high blood pressure on
dialysis should be treated should be individualized.
Statin treatment
Despite the negative outcome of the German 4-D study
[22], we still believe that statins are a useful agent in
the treatment of CKD patients, at least those with CKD
or dialysis patients with manifest coronary heart
disease. Controlled prospective trials on patients with
diabetes or heart disease, particularly those with mild
to moderate impairment of renal function, showed that
they obtained major benefit from statins [33]. The
argument is rendered even more interesting by the
recent result of a meta-analysis indicating that treatment
of CKD patients with statins is associated with minor,
but statistically significant, less loss of renal function
[34]. The negative outcome in the 4-D study is mainly
explained by the relatively low frequency of adjudicated
coronary death (which is apparently responsive to statin
treatment) because lowering of low-density lipoprotein
cholesterol by 1 mmol achieved a 19% reduction in
coronary deaths—exactly what had been observed in
non-dialysed patients. Apparently, the other causes of
death are not due to cardiac ischemia resulting from
coronary disease and the final answer will have to wait
for the sufficiently powered SHARP study.
An alternative, or complementary explanation, may
be that in uremic compared to non-renal patients with
coronary heart disease, the coronary plaques show more
intense inflammatory changes (higher C-reactive protein,
terminal complement complex C5b-9) and more intense
macrophage infiltration, expression of markers of fibrosis
(transforming growth factor-`, collagen IV, endothelin
1) and, particularly, more intense deposition of
glycophorin, an erythrocyte membrane protein, evidence
of past hemorrhage into coronary plaques [35].
It has recently been claimed that statins reduce the
risk of septicemia in CKD patients, a finding that we
could not confirm in the 4-D study.
Beta-blockers
In an observational study on hemodialysed type 2
diabetic patients, Koch et al [36] noted that only 4% of
patients who died, but 12% of patients who survived,
had received beta-blockers; the same had been observed
in the URREA study [37].
In dialysed patients with dilated cardiomyopathy,
Cice et al [38] observed that the rate of cardiovascular
death in patients randomized to receive placebo was
67.9%, whereas that of patients randomized to receive
carvedilol was 29.3%, and a similar reduction was seen
with respect to hospitalization.
There is very little chance that a prospective
randomized trial of beta-blockers with adequate size
will ever be performed in dialysis patients. The available
evidence, however, would strongly suggest that beta-
blockers be used, particularly in view of the excess
sympathetic activity in patients on dialysis [39] and the
frequency of sudden death [40]. Because of the many
metabolic and circulatory side effects of classical beta-
blockers, we prefer the use of carvedilol [41] or
nevibolol.
Blockade of the renin-angiotensin system
In the PEACE trial on the use of trandolapril in patients
at low cardiovascular risk, the overall result was
completely negative. Surprisingly, however, Solomon
et al [42] noted that in patients with eGFR < 60 mL/
min, trandolapril treatment achieved significant benefit,
suggesting either that the renin-angiotensin system is
more activated in early CKD or that it is more
responsive to blockade. The administration of
angiotensin-converting enzyme inhibitors (ACEIs) in
patients with early and advanced CKD is safe,
particularly with respect to hyperkalemia [43], but
unfortunately, in elderly hemodialysed patients, per
protocol analysis of a French study found no significant
benefit from fosinopril (relative risk, 0.79; p < 0.09)
[44]. Thus, there is currently no controlled evidence
for the efficacy of ACEIs.
The situation is somewhat better with respect to
angiotensin receptor blockers (ARBs). In an
unpublished study, Cice found that hemodialysis
patients with heart failure who had received telmisartan
on top of alternative therapy, including ACEIs, had
significantly (p < 0.01) better survival over 36 months.
This result (presented so far only in abstract form)
requires confirmation.
Some small preliminary underpowered Japanese
studies suggest less cardiovascular mortality in patients
on ARBs and a larger study is currently ongoing.
One important consideration is the fact that blockade
of the renin-angiotensin system increases the duration
of residual diuresis, which is a most powerful predictor
of survival [45]. It has been shown that while diuretics
augment residual diuresis, they fail to prolong its
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persistence [46]. In contrast, prospective studies in
peritoneal dialysis patients documented that both
ramipril [47] and valsartan [48] prolonged persistence
of residual diuresis.
Finally, a study on 43,200 prevalent hemodialysis
patients of the Gambro Healthcare System in the USA
with 729 cases of cardiac arrest found that the relative
chance of survival was improved by beta-blockers (odds
ratio, 0.60) and by ACEIs or ARBs (odds ratio, 0.53)
[49].
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